Since
2023
France
Therapeutics
TRL 4

Challenge

Approximately half a billion people between the age of 30 and 69 suffer from the most common type of sleep-related breathing disorder, obstructive sleep apnea (OSA). OSA prevalence is rising and its effects are detrimental to both the patient’s daily well-being and productivity in workplace and their motor vehicle safety. 

 

Opportunity

Currently, the gold-standard treatment of OSA is continuous positive airway pressure (CPAP). However, CPAP has a 15% initial refusal rate because up to 50% of the patients drop out in the first three years of treatment. Non-CPAP therapies (e.g., oral appliance therapy and upper airway surgery) have varied and unpredictable efficacy and can be expensive. 

 

Solution

Pasithea’s mechanism of action is based on non-invasive triggered kinesthetic stimulation. Pasithea is able to detect the early phase of apnea or hypopnea and induces a controlled startle response. This can, then, activate sub-cortical centres controlling upper airways muscles, and, thus, limit the associated oxygen desaturation and tachycardia. The latter are linked to an increased risk of cardiovascular morbidity.

 

Status

Pasithea has already been granted 8 patent certificates. The company is now focusing on the miniaturization of the device and on ensuring compliance with medical device requirements (CE mark and FDA approval). 

 

Meet the team

Pierre Ansay

Pierre Ansay

CEO

Alfredo Hernández Inventor

Alfredo Hernández

Inventor

Jean-Louis-Pepin-150x150

Jean-Louis Pépin

Inventor

Pieter Wijffels (1)

Pieter Wijffels

Venture partner at NLC

Pieter joined NLC in April 2020 as a Venture Partner. Before joining NLC, he spent 15 years at Philips, bringing innovation to life across the globe. He enjoys working in fast-paced environments and supporting initiatives that truly improve people’s lives.

NLC Health Ventures Footer